Enovis Corporation (ENOV)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Oct 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	1.30B	1.25B	1.15B
United States Revenue Growth	4.49%	8.10%	8.43%
Foreign Locations Revenue	931.71M	861.95M	554.84M
Foreign Locations Revenue Growth	8.09%	55.35%	10.89%
Revenue (Total)	2.23B	2.11B	1.71B
Revenue (Total) Growth	5.96%	23.46%	9.22%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Oct 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
U.S. Bracing & Support Revenue	487.10M	469.32M	456.13M
U.S. Bracing & Support Revenue Growth	3.79%	2.89%	4.31%
U.S. Other P&R Revenue	279.10M	270.74M	269.83M
U.S. Other P&R Revenue Growth	3.09%	0.34%	5.69%
International P&R Revenue	374.84M	357.90M	350.82M
International P&R Revenue Growth	4.73%	2.02%	4.71%
Total Prevention & Recovery Revenue	1.14B	1.10B	1.08B
Total Prevention & Recovery Revenue Growth	3.92%	1.97%	4.78%
U.S. Reconstructive Revenue	535.36M	505.62M	426.41M
U.S. Reconstructive Revenue Growth	5.88%	18.58%	15.19%
International Reconstructive Revenue	556.87M	504.05M	204.02M
International Reconstructive Revenue Growth	10.48%	147.06%	23.42%
Total Reconstructive Revenue	1.09B	1.01B	630.42M
Total Reconstructive Revenue Growth	8.18%	60.16%	17.73%
Total Medical Technology Revenue	2.23B	2.11B	1.71B
Total Medical Technology Revenue Growth	5.96%	23.46%	9.22%
Revenue (Total)	2.23B	2.11B	1.71B
Revenue (Total) Growth	5.96%	23.46%	9.22%

Adjusted EBITDA

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Oct 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Prevention & Recovery Adjusted EBITDA	167.69M	159.60M	152.50M
Prevention & Recovery Adjusted EBITDA Growth	5.07%	4.65%	7.89%
Reconstructive Adjusted EBITDA	236.27M	216.92M	116.73M
Reconstructive Adjusted EBITDA Growth	8.92%	85.84%	23.23%
Operating Income (Total)	-47.54M	-775.72M	-65.71M

Capital Expenditures

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Prevention & Recovery Capital Expenditures	34.00M	26.36M
Prevention & Recovery Capital Expenditures Growth	29.02%	4.84%
Reconstructive Capital Expenditures	146.71M	95.87M
Reconstructive Capital Expenditures Growth	53.03%	28.84%
Total Medical Technology Capital Expenditures	180.71M	122.22M
Total Medical Technology Capital Expenditures Growth	47.86%	22.78%

Updated Nov 6, 2025. Data Source: Fiscal.ai.